Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly

Inclusion Criteria: * Inclusion Criteria to be checked at the screening visit (SC): * Aged 0 to 7 days on the day of screening * Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg * Informed consent form signed by the parent(s) or other legally acceptable representative * Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures * Inclusion Criteria to be checked at the randomization visit (V01): * Aged 42 to 50 days on the day of inclusion * Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures Exclusion Criteria: * Exclusion Criteria to be checked at the screening visit (SC): * Planned participation in another clinical trial during the present trial period * Illness that could interfere with trial conduct or completion, in the opinion of the investigator * Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response * History of seizures * Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity * Thrombocytopenia or bleeding disorder contraindicating IM injection * Exclusion Criteria to be checked at the randomization visit (V01): * Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination * Planned participation in another clinical trial during the present trial period * Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy * Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances * Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator * Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response * Receipt or planned receipt of any vaccine in the 4 weeks preceding or following any trial vaccination (except BCG, DTP-Hib or Hepatitis B vaccines, which can not be given within 10 days before or after any study vaccination) * History of seizures * Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity * History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically) * Previous vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine * Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) injection * Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment